Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of PF-07104091 Formulations and Food Effect
NCT05431153Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tegtociclib in breast cancer, ovarian cancer and solid tumor (6 arms), sponsored by Pfizer. Primary endpoints: Area Under the Plasma-Concentration Time Curve From Time Zero Extrapolated to Infinity at 48 hours and Maximum Observed Plasma Concentration at 48 hours. Started Jun 2022; status: completed.
02
Drugs
tegtociclib
03
Conditions
breast cancerovarian cancersolid tumor
Beyond the preview
Go deeper on NCT05431153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05431153.